ARxVision integrates with Microsoft Seeing AI app and Navilens app to enhance accessibility solutions for blind, low vision patients


The company noted that individuals can purchase the ARx AI headset and register for access to the Seeing AI app through the provided links or download the latest version of the NaviLens app.

Image credit: AdobeStock/Bipul Kumar

(Image credit: AdobeStock/Bipul Kumar)

ARxVision announced the integration of its groundbreaking ARx AI Gen1.5 wearable headset with Microsoft’s Seeing AI app and the Navilens App.

According to the company, the SeeingAI app is a visual assistant designed to narrate the world for people who are blind or have low vision. The app can support individuals with a variety of daily tasks such as reading mail, identifying everyday products, or hearing descriptions of photos. The company noted that the collaboration marks an advancement in accessibility solutions for the blind and low-vision communities worldwide.

The Royal National Institute of Blind People (RNIB) is the global distributor for the ARx AI headset, ensuring its broad availability and impact.1

Following the integration of the Microsoft Seeing AI app, ARx AI Gen1.5 users can now access a comprehensive suite of AI-powered functionalities directly through the ARx AI headset, providing support and independence.

"At ARxVision, we're on a mission to empower individuals everywhere, regardless of their abilities, to reach their full potential in daily life," Charles Leclercq, CEO of ARxVision, said in a news release. "This collaboration, aligned with the launch of the ARx AI Gen1.5 headset, marks the first exciting step towards an open platform that fosters global accessibility.“

Leclercq added the company is pleased by how ARx leverages AI to enhance independence, employment opportunities, and access to healthcare, culture, and beyond, a sentiment echoed by Saqib Shaikh, software engineering manager and lead and founder of Seeing AI, Microsoft

"We are pleased to work with ARxVision and integrate Seeing AI with their ARx AI Gen1.5 headset,” Shaikh said in a news release. “This integration will bring hands-free access to Seeing AI and enable seamless access to information to users who are blind or have low vision.”

Javier Pita, CEO, and founder of NaviLens, said the company is pleased to be participating in this partnership.

“We are very excited to partner with ARxVision in integrating NaviLens with their incredible device.,” Pita said in a news release. “Now, anybody will be able to use cutting-edge NaviLens technology hands-free! This marks a remarkable stride towards NaviLens' mission: to realize a world that is more inclusive for individuals who are blind or have low vision.”

According to the news release, with the integration of the NaviLens app, users can now scan the accessible NaviLens codes at public transit facilities across the world in cities like London, New York, Barcelona, Madrid, Amsterdam, Tokyo, Singapore, Melbourne, and many more, providing a seamless experience.

Moreover, the ARx AI Gen1.5 headset features cutting-edge technology, including a 4K/8 Mega Pixel camera, enhanced audio, and improved button responsiveness. With a focus on user experience, the ARx app offers a premium interactive onboarding tutorial, integration of Large Language Models, and more offline functionalities. Furthermore, the partnership with RNIB ensures that the ARx AI headset is accessible globally, with support from other organizations such as CNIB, National Federation of the Blind (NFB), and Vision Australia.

The pilot program will offer the ARx AI Gen1.5 headset and app at a discounted price of $599, with 150 units ready to ship immediately within the USA. Beyond the initial allocation, people can also register for pre-orders, with shipments expected within 3 to 6 months.

The product discount is available until May 31, and a limited inventory Is available. The release is scheduled soon in the UK, US, Australia and Canada.

1. RNIB. Welcome to RNIB. RNIB - See differently. Published 2014. Accessed March 19, 2024.
© 2024 MJH Life Sciences

All rights reserved.